Jonas Wang is the CEO and president of Stemcyte International Ltd. Stemcyte, which Dr. Wang joined in January of 2009, is expected to go public in Taiwan later this year. He is also currently a consultant partner of Sycamore Ventures in New Jersey, focusing on life sciences and biotechnology investments.
Dr. Wang has over 30 years of experience in pharmaceutical R&D management and business development. Prior to joining Sycamore Ventures, he was vice president of Research and Technology at Johnson & Johnson Consumer Products and a corporate director of J&J Drug Delivery Technology Resource Center (TRC), responsible for new product technology, patent strategy, competitive intelligence, and new measurement methodology for skin and hair care franchise. Prior to that, Dr. Wang was an associate director of Basic Pharmaceutics, the Pharmaceutical Research Institute of Bristol-Myers Squibb Co. Additionally, in 2001, he participated at the Congressional Business Summit in Washington, DC, leading the group exploring emerging markets in America.
Dr. Wang was also a member of J&J Consumer Product Worldwide’s L&A Committee and was the key driver for several major acquisitions. He has published extensively in drug delivery technology and received several major awards in his field, including the Johnson Medal, the highest technical achievement award at J&J, for one of his inventions: anti-wrinkle cream. During his career with J&J, Jonas developed more than 10 core technologies and filed more than 30 business-related patents. He is currently a member of the boards of directors of StemCyte Inc., U-Systems Inc., Epitomics Inc., a board observer of Transave Inc. and Cardiva Inc, and a business advisor of Xylos Corporation.
He received distinguished alumni awards from the National Defense Medical Center and University of Iowa.
Dr. Wang received his doctorate in physical pharmacy from University of Iowa in 1982 and his Bachelor of Science pharmacy degree from National Defense Medical Center in Taiwan, Republic of China.